News

WASHINGTON and SAN FRANCISCO, Oct. 31, 2023 – For the third consecutive year, Martis Capital Management, LLC (Martis Capital), a healthcare-focused private equity firm, has been named to Inc. magazine’s Founder-Friendly Investors list, recognizing the private equity and venture capital firms with the best track records of success backing entrepreneurs.

Introduced in 2019, the Inc. Founder-Friendly Investors list is considered the go-to guide for entrepreneurs who want to grow their companies while retaining a meaningful ownership stake. As part of the evaluation process, Inc. interviewed founders to learn about their experiences and collected data on how their companies have grown as a result of these partnerships. Of the 218 firms honored, Martis Capital was one of eight healthcare-exclusive private equity firms listed and one of only three healthcare-exclusive firms to be recognized for a third consecutive year.

“This industry acknowledgment is particularly rewarding to us because it honors the importance of partnerships between founders, their teams and their investors,” said Owen Davis, managing partner of Martis Capital.

“We envision a new era in U.S. healthcare defined by better patient outcomes through value-based care and data-driven decision support,” said Justin Dangel, chairman of Martis portfolio company Rise Health.  “Martis’ experience and its transparent, collaborative and partnership mentality have enabled us to execute on our shared vision.”

“Inc. magazine is devoted to providing entrepreneurs with all the tools and resources they need to start, run, grow, and sometimes exit their businesses,” said Scott Omelianuk, editor-in-chief of Inc. media. “The 2023 Founder-Friendly Investors list is our way of guiding entrepreneurs to proven partners they can trust and collaborate with while receiving the financial support they need to accelerate growth.”

To see the complete list of Inc.’s Founder-Friendly Investors, visit https://www.inc.com/founder-friendly-investors/2023

About Martis Capital

Based in Washington, DC and San Francisco, Martis Capital is a founder-friendly capital partner for growth-oriented healthcare companies. Since 2011, Martis Capital has raised more than $2.2 billion from a global base of institutional clients to invest in the middle-market North American healthcare sector. For more information, visit www.martiscapital.com.

Media Contacts

Newton Park PR, LLC

Margaret Kirch Cohen
+1 847 507 2229
margaret@newtonparkpr.com

Richard Chimberg
+1 617 312 4281
rich@newtonparkpr.com

In October 2023, WellHaven PetHealth acquired Blue Cross Veterinary Clinic in Arizona, marking partnerships in six active markets for WellHaven. “We are thrilled to welcome the Blue Cross Veterinary Clinic to the WellHaven family,” shared CEO, Jenni Jones. “We are thankful for the compassionate care they provide and look forward to helping them continue their mission of providing quality pet care.”

“It’s been a privilege to work with Jenni Jones and the WellHaven team to continue our de novo and acquisition strategy as we expand across the U.S.” commented Martis Capital Managing Partner, Owen Davis.

About WellHaven

Founded in 2017, WellHaven PetHealth was started by Martis as a multi-regional platform of veterinary practices providing a full range of veterinary services including internal medicine, emergency medicine, surgery, oncology, dentistry, dermatology, grooming, boarding, pharmacy, laboratory, and radiology services. WellHaven now has more than 40 hospitals across Colorado, Minnesota, Washington, Oregon, Montana and Arizona.

Martis Capital, a middle-market private equity firm focused exclusively on the healthcare industry, announced that Chris Beall has been promoted to Partner.

During his tenure at Martis, Chris has been an active contributor, closing five platforms as well as leading the firm’s most recent investment in Dental Associates of Connecticut (DACT).  Chris was also instrumental in the successful exits of HHA eXchange, Altruista Health, and Care Hospice.  He currently serves on the Board of Directors of Qualifacts, Community Based Care, and DACT.

Prior to joining Martis in 2014, Chris was an Associate at Quad-C Management and previously worked in investment banking in the Retail & Consumer Group at Citi.  He received a BS in Commerce from the McIntire School of Commerce at the University of Virginia.

“It’s been rewarding to see Chris grow and develop during his time at Martis, and we are very excited to now have him as a Partner in the firm leading investments and helping to manage portfolio companies alongside us,” said Founder and Managing Partner, Barry Uphoff.

Based in Washington, DC and San Francisco, Martis Capital is a founder-friendly capital partner for growth-oriented healthcare companies. Since 2011, Martis Capital has raised more than $2.2 billion from a global base of institutional clients to invest in the middle-market North American healthcare sector. For more information, visit www.martiscapital.com.

Alcanza Clinical Research announces the acquisition of Accel Research Sites Network, a multi-specialty network headquartered in Florida, with additional sites in Alabama and Georgia. As a leader in medical research since 1998, Accel’s network of 22 sites includes eight clinical research units and 14 embedded sites strategically placed in healthcare settings across the Southeast U.S.

“The addition of Accel to the Alcanza network is part of our strategy to operate with greater scale and therapeutic specialization to reach more patient populations who are not traditionally presented with research participation opportunities,” said Carlos Orantes, CEO of Alcanza. “Accel’s breadth of therapeutic expertise, reputation for on-time enrollment and their access to diverse patient populations are a perfect complement for Alcanza’s growth portfolio.”

“We are looking for a partner with aligned vision to further our mission of patient-centric clinical research while reducing barriers to participation,” said Dr. Lora Parahovnik, CEO of Accel. “That partner is Alcanza. This move will enable us to conduct clinical trials more efficiently, effectively, and inclusively than ever before. Together, we’ll be able to offer more opportunities for patients to participate in clinical research, and we’ll be better positioned to recruit and retain high-quality research staff.”

Accel’s site operations will be integrated into Alcanza’s centralized platform while retaining its name and brand identity.

About Alcanza Clinical Research

Alcanza Clinical Research is an integrated network of research facilities focused on bringing clinical trial opportunities involving life-changing treatments and vaccines to all patients, especially those from under-represented communities. With locations in Alabama, Florida, Georgia, Massachusetts, Michigan, New Hampshire, South Carolina, and Virginia, we specialize in a range of conditions across allergy, cardiology, dermatology, endocrinology, immunology, infectious disease, neurology, ophthalmology, psychiatry, and respiratory therapeutic areas.

Martis Capital Management, LLC (Martis Capital), a healthcare-focused private equity firm, has closed its fourth fund, Martis Partners IV, LP (Fund IV), with $779 million in capital commitments, exceeding its target of $700 million.

Fund IV’s commitments come from a diverse group of existing and new individual and institutional investors globally. With the new fund, Martis Capital has raised more than $2.1 billion in capital to date.

“We are grateful for the ongoing and enthusiastic support from our existing and new investors,” said Barry Uphoff, founder and managing partner at Martis Capital.

Martis Capital invests in buyout and growth equity opportunities in middle-market companies providing innovative and cost-effective products and services within the services and outsourcing, information technology, and consumer and wellness subsectors of the North American healthcare industry.

“Our team continues to execute on our consistent strategy, and we are well positioned to deploy capital within our growth targets,” said Mario Moreno, managing partner.

The firm has made three investments from Fund IV in companies specializing in clinical research trials, value-based primary care, and comprehensive dental care.

“Fund IV, our largest to date, is off to a great start. Our three initial investments are performing well, a testament to the quality of our partner companies and the research and due diligence of the Martis Capital team,” said Owen Davis, managing partner.

Martis Capital is the only dedicated healthcare PE firm to receive both Grady Campbell’s Top 50 PE Firms Award and Inc. Magazine’s Founder-Friendly Investors Award in 2022 and 2021. The firm is also among GrowthCap’s Top 25 Healthcare Investors of 2023.

Metric Point Capital was the primary placement agent, and McDermott Will & Emery LLP served as legal counsel.

About Martis Capital

Based in San Francisco and Washington, DC, Martis Capital is a founder-friendly capital partner for growth-oriented healthcare companies. Since 2011, Martis Capital has raised more than $2.1 billion from a global base of institutional clients to invest in the middle-market North American healthcare sector. For more information, visit www.martiscapital.com.

Martis Capital is excited to have been named a Top 50 PE Firm in the Middle Market for the third consecutive year. Top PE Firms in the Middle Market™ is the oldest and most highly regarded award program, and we are honored to receive this nomination as a reflection of our deep industry expertise and thoughtful investment approach.

Martis was one of just three healthcare exclusive private equity firms to receive this award in 2023, and the only healthcare exclusive firm recognized for more than one year in a row.

Martis did not pay a fee as part of the selection process.  To read more about the Top 50 PE program and view a detailed list of winning firms, please visit TOP 50 PE Firms — GCI Publishing.